Article Information
- Received March 1, 2012
- Accepted May 14, 2012
- Published online July 16, 2012.
Article Versions
- Earlier version (May 15, 2012 - 12:05).
- You are viewing the most recent version of this article.
Author Information
- Mònica Aparici,
- Mireia Gómez-Angelats1,
- Dolors Vilella,
- Raquel Otal,
- Carla Carcasona,
- Marisa Viñals,
- Israel Ramos,
- Amadeu Gavaldà,
- Jorge De Alba,
- Jordi Gras,
- Julio Cortijo,
- Esteban Morcillo,
- Carlos Puig,
- Hamish Ryder2,
- Jorge Beleta and
- Montserrat Miralpeix
- Almirall R&D Center, Sant Feliu de Llobregat, Barcelona, Spain (M.A., M.G.-A., D.V., R.O., C.C., M.V., I.R., A.G., J.D.A., J.G., C.P., H.R., J.B., M.M.); Department of Pharmacology, Faculty of Medicine, University of Valencia, Valencia, Spain (J.C., E.M.); Ciber Respiratory Diseases, Valencia, Spain (J.C., E.M.); Research Foundation, University General Hospital, Valencia, Spain (J.C.); and Clinical Pharmacology Unit, Research Foundation, University Clinic Hospital, Valencia, Spain (E.M.)
- Address correspondence to:
Dr. Mònica Aparici, Almirall S.A., Laureà Miró, 408-410, 08980 Sant Feliu de Llobregat, Barcelona, Spain. E-mail: monica.aparici{at}almirall.com
This work was partially presented in abstract form: Aparici M, Gómez-Angelats M, Vilella D, Cortijo J, Morcillo E, Carcasona C, Gavaldà A, Beleta J, Puig C, Ryder H, et al. (2010) The in vitro pharmacological profile of LAS100977–a potent, selective and long-acting β2 receptor agonist, at the American Thoracic Society Meeting, 2010 May 14–19, New Orleans, LA, American Thoracic Society, New York, NY. Miralpeix M, Gómez-Angelats M, Aparici M, Viñals M, Beleta J, Gavaldà A, Puig C, Ryder H, Llenas J and Gras J (2010) LAS100977, a novel β2 receptor agonist, with a longer duration of action and more favorable safety margin than salmeterol in anesthetized dogs, at the American Thoracic Society Meeting, 2010 May 14–19, New Orleans, LA, American Thoracic Society, New York, NY. Aparici M, Gómez-Angelats M, Vilella D, Cortijo J, Morcillo E, Carcasona C, Gavaldà A, Beleta J, Puig C, Ryder H, et al. (2010) LAS100977 is a novel, potent β2-agonist with rapid onset and sustained duration of action in isolated human bronchi, at the European Respiratory Society Meeting, 2010 Sept 18–22, Barcelona, Spain, European Respiratory Society, Lausanne, Switzerland. Miralpeix M, Gómez-Angelats M, Aparici M, Viñals M, Beleta J, Gavaldà A, Puig C, Ryder H, Llenas J, and Gras J (2010) LAS100977, a novel β2-agonist, has a longer duration of action and a more favorable therapeutic index than salmeterol in anesthetized dog, at the European Respiratory Society Meeting, 2010 Sept 18–22, Barcelona, Spain, European Respiratory Society, Lausanne, Switzerland.
